Updated COVID vaccines prevented illness from latest variants -CDC
Send a link to a friend
[January 26, 2023]
By Julie Steenhuysen and Raghav Mahobe
(Reuters) -The updated COVID-19 boosters from Pfizer Inc/BioNTech SE and
Moderna helped prevent symptomatic infections against the new XBB-related
subvariants, offering new evidence of how the vaccines perform against
these fast-spreading strains, U.S. officials said on Wednesday.
"Today we have additional evidence to show that these updated vaccines
are protecting people against the latest COVID-19 variants," Dr. Brendan
Jackson, head of the U.S. Centers for Disease Control and Prevention's
COVID-19 response, told reporters in a briefing.
Released last fall, the updated boosters target the BA.4 and BA.5
Omicron variants of the SARS-CoV-2 virus, which are no longer dominant.
The now-dominant XBB-related subvariants are derived from the BA.2
version of Omicron.
Lab studies had suggested that vaccine protection was lower against the
XBB variants compared with prior variants, raising questions about how
well the vaccines worked against these rising strains of the virus,
Jackson said.
For the study, researchers reviewed COVID-19 cases from Dec. 1 through
Jan. 13, a period in which U.S. circulation of XBB and XBB.1.5
increased. It showed that the updated vaccine helped prevent illness in
roughly half of the people who had previously received two to four doses
of the original COVID-19 vaccine, CDC said.
The CDC said the updated vaccine worked similarly against BA.5-related
infections and XBB/XBB.1.5-related infections. It was 52% effective at
preventing infections against BA.5 and 48% against XBB/XBB.1.5 among
those aged 18-49. Effectiveness fell to 37% against BA.5 and 43% against
XBB/XBB.1.5 among those aged 65 years and older.
[to top of second column]
|
A vial of the Pfizer-BioNTech
coronavirus disease (COVID-19) booster vaccine targeting BA.4 and
BA.5 Omicron sub variants is pictured at Skippack Pharmacy in
Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah
Beier
Although not reflected in the study,
Jackson said data to be released later on Wednesday shows the
updated vaccine reduced the risk of death from COVID-19 by more than
twofold compared with vaccinated people who had not received the
updated booster. The updated shot also reduced the risk of death
from COVID-19 by nearly 13-fold in people who are unvaccinated.
Study author Ruth Link-Gelles of the CDC said overall, the vaccines
cut the risk of symptomatic infection by about half on a population,
but individuals see a different benefit based on their risk factors.
Link-Gelles said the estimates are for symptomatic infection, which
CDC defined as one or more symptom of COVID-19. Given the findings,
the CDC urged people to stay up to date on their recommended
COVID-19 vaccines.
XBB.1.5 was estimated to make up nearly half of U.S. cases in the
week ended Jan. 21, government data showed.
The CDC analysis comes ahead of a meeting on Thursday at which
outside experts to the U.S. Food and Drug Administration are
expected to discuss whether and how the United States should offer
the COVID vaccine as an annual shot.
(Reporting by Raghav Mahobe in Bengaluru and Julie Steenhuysen in
ChicagoEditing by Caroline Humer and Matthew Lewis)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|